Navigation Links
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Date:5/9/2013

ience to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

About Zhejiang Beta Pharma Co., Ltd.
Zhejiang Beta Pharma is a leading innovative pharmaceutical company in China with fully integrated capabilities that include R&D, GMP manufacture, sales and marketing.  We were founded in 2003 and are headquartered in Hang-Zhou with R&D operations in Beijing.  Over the last 10 years, we have been dedicated to the development of novel therapeutics and launched Icotinib in 2011 for the treatment of NSCLC patients in China.  Going forward, we will continue to focus on pharmaceutical innovation so that we can benefit many more patients.  For more information, visit www.betapharma.com.cn.

About Vectibix
Vectibix is a prescription medicine used for the treatment of metastatic colorectal cancer (mCRC). It is grouped within a class of medications called biologics, which are therapies derived from human cells. Vectibix is approved in more than 40 countries. 

Vectibix is the first fully human anti-epidermal growth factor receptor (EGFR) antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC). Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.

Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... issued the following statement today in support of President ... "As the global leader in rapid diagnostics ... a national strategy to address the serious threat of ... with the Administration on initiatives to promote the development ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Nerve Growth Factor Has Demonstrated Promising Activity Preclinically-- , ... Huntington,s Disease and Others-- , , RESEARCH TRIANGLE ... clinical stage company developing and commercializing innovative treatments for ... that it has obtained the rights to develop and ...
... June 15 Vitamin D deficiency was found to be ... the results of a recent study conducted at ... these results, CTCA researchers determined that screening for vitamin D ... all people with cancer. , , (Logo: ...
Cached Medicine Technology:CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 2CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 3Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients 2
(Date:9/20/2014)... September 20, 2014 The print ... today’s edition of the Calgary Herald, with a ... readership of 270,000. The digital component is distributed ... across a network of top news sites and ... the campaign, visit http://www.worklifebalanceinfo.ca . , The ...
(Date:9/20/2014)... -- The avian flu that killed 160 harbor seals ... respiratory drops and therefore poses a potential threat to ... human illnesses have been linked to the harbor seal ... discovered natural mutations to the avian H3N8 seal virus ... in droplets. Current seasonal flu vaccines wouldn,t help ...
(Date:9/20/2014)... festival season is coming soon. The high-end fashion designer BellasDress ... dresses . A lot of sophisticated women like its new ... promotion for its high quality clothes. Now, each of its ... to 71 percent off. , The company’s cocktail dress ... in many fashionable colors. Mary, the company’s sales manager, believes ...
(Date:9/20/2014)... TX (PRWEB) September 20, 2014 ... Forecast and Market Analysis to 2023?. The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ...
(Date:9/20/2014)... the popular online supplier of wedding dresses and special ... collection of cocktail gowns. This afternoon, the company announced ... outfits; it intends to expand its online market in ... cocktail dresses in the company’s online store. ... experience in the industry of women’s special occasion dresses. ...
Breaking Medicine News(10 mins):Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2
... Dynatronics,Corporation (Nasdaq: DYNT ) today announced ... Mike Draper and Tom Draper, both of Wichita, ... as direct sales representatives. Dynatronics now offers ... our direct distribution presence is helping improve,profit margins ...
... BIRMINGHAM, Ala., Oct. 10 Aeon Bioscience,Inc. ... of its key,collaborators, Brookwood Pharmaceuticals, Inc. by ... to develop improvements in drug-eluting stent,technology for ... Bioscience was formed as a collaborative enterprise ...
... Achievement,and Innovation in Patient-Centered Approaches to Care, ... Hospital of,Warrenton, VA has been formally recognized ... Hospital." This designation,recognizes Fauquier,s achievement and innovation ... prioritizes patient comfort, dignity, empowerment,and well-being, while ...
... eHI Blueprint Offers Multi-Stakeholder Consensus on a Shared Vision, ... ... Through Information Technology, WASHINGTON, Oct. 10 Today the ... Common Action, which represents multi-stakeholder,consensus on a shared vision and ...
... A report to be published in an upcoming issue ... urgent attention to the politically sensitive issue of border control, ... the face of a catastrophic flu pandemic . The ... a strain of avian influenza A (HN51) in Northern Sumatra: ...
... Oct. 10 CBIZ, Inc. (NYSE: CBZ ) has,scheduled ... a.m.,(ET) to discuss the Company,s financial results for the third-quarter ... the,market opens the morning of October 25, 2007. At that ... Company,s web site at http://www.cbiz.com . The call ...
Cached Medicine News:Health News:Dynatronics Adds Three Additional Direct Sales Reps 2Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 2Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 3Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 4Health News:Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital 2Health News:Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital 3Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 2Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 3Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 4Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:CBIZ Webcasts Third-Quarter 2007 Conference Call 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Requires minimal cervical spine manipulation. Prevent dental ... nasally. Cost effective alternative to X-ray. Light-guided ... the soft tissues in the neck. This ... of the trachea relative to the esophagus. ...
Medicine Products: